Curemark
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
800 Westchester Ave Ste S528, Rye Brook,...Phone Number
(914) 824-9700Website
www.curemark.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Curemark
Galenagen is a wholly-owned subsidiary of Curemark, LLC, a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Galenagen LLC is focused on antibacterial and antiviral treatments as well as medical devices. Curemark's pipeline includes preclinical and clinical-stage programs for the treatment of autism, ADHD, addiction, schizophrenia and Parkinson's disease.Explore more
Curemark Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Curemark your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Curemark recently announced quarterly report
Funding: Get notified immidiatlly once Curemark has new funding data
Product Launch: Get notified when Curemark launches new products
Check out if Curemark is spiking on competitors!
Check if Curemark has recently received funding, and reach out quickly before it becomes old news!
Click to see if Curemark had a recent Job posting/layoffs
Curemark, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Curemark
Recommended Actions
Find VP level buyers at Curemark
Find 3 more new buyers
Compare Similar Companies to Curemark
Compare insights from companies similar to Curemark, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Public
$355.8M
2018
ST
Samantha TracyAnalysis & Investor Relations Senior Director, Financial Planning
Company Profile Activity
Activity Insights
Curemark is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Curemark is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Curemark.
Curemark financials insights
Gather financial insights about Curemark, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Debt
$6M
2013
Private Equity
$18.5M
2014
Debt
$5M
2015
Private Equity
$20.3M
2017
Private Equity
$3M
2018
Private Equity
$3.2M
2020
Debt
$150K
Curemark Tech Stack
A closer look at the technologies used by Curemark
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Board of Directors
New Hire
Executive Move
New Hire
Executive Move
Executive Moves, New Hire
Funding
Curemark News & Media
Curemark Announces the Addition of Christopher Varelas to the Board of Directors
RYE BROOK, N.Y., Feb. 1, 2024 /PRNewswire/ -- Curemark, LLC announced the appointment of Chris Varelas to its Board of Directors. Mr. Varelas is a Co-founding Partner of Riverwood Capital, an investment firm focused on high-growth technology and technology-related companies. Prior to...JAMA Publishes Article Showing Long-Term Improvement in Autism with Curemark's Pancreatic Replacement Therapy
RYE BROOK, N.Y., Dec. 4, 2023 /PRNewswire/ -- Curemark today announced the publication of their long-term clinical data demonstrating disease/disorder modification in maladaptive behaviors in children as young as 3 years of age with Autism Spectrum Disorder (ASD). The paper entitled...Curemark Announces the Addition of Stacy E Grant as the Senior Vice President of Corporate Strategy and Finance
RYE BROOK, N.Y., April 10, 2023 /PRNewswire/ -- Curemark announced today that Stacy E. Grant will join the company as Senior Vice President of Corporate Strategy and Finance, effective immediately. Previously, Ms. Grant was a Managing Director at Morgan Stanley and enjoyed a successful...Curemark Appoints Dr. William R. McIntyre as Senior Vice President
Curemark announced today the key addition of Dr. William R. McIntyre to the team as the Senior Vice President of Global Regulatory... Read More The post Curemark Appoints Dr. William R. McIntyre as Senior Vice President appeared first on citybiz.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Curemark
Sign Up For FreeTo access detailed company insights
Galenagen is a wholly-owned subsidiary of Curemark, LLC, a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Galenagen LLC is focused on antibacterial and antiviral treatments as well as medical devices. Curemark's pipeline includes preclinical and clinical-stage programs for... Read More
